



Published in final edited form as:

*J Am Chem Soc.* 2016 December 14; 138(49): 15837–15840. doi:10.1021/jacs.6b10452.

## Biochemical Characterization of a Eukaryotic Decalin-Forming Diels–Alderase

Li Li<sup>1,2</sup>, Peiyuan Yu<sup>3</sup>, Man-Cheng Tang<sup>2</sup>, Yi Zou<sup>2</sup>, Shu-Shan Gao<sup>2</sup>, Yiu-Sun Hung<sup>2</sup>, Muxun Zhao<sup>2</sup>, Kenji Watanabe<sup>4,\*</sup>, K. N. Houk<sup>2,3,\*</sup>, and Yi Tang<sup>2,3,\*</sup>

<sup>1</sup>Engineering Research Center of Industrial Microbiology (Ministry of Education) and College of Life Sciences, Fujian Normal University, Fuzhou 350117, P. R. China

<sup>2</sup>Department of Chemical and Biomolecular Engineering, University of California, Los Angeles, California 90095, United States


<sup>3</sup>Department of Chemistry and Biochemistry, University of California, Los Angeles, California 90095, United States

<sup>4</sup>Department of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan

### Abstract

The *trans*-decalin structure formed as a result of intramolecular Diels–Alder cycloaddition is widely present among bioactive natural products isolated from fungi. In this work, we elucidated the concise, three-enzyme biosynthetic pathway of the cytotoxic myceliothermophin and biochemically characterized the Diels–Alderase (DAase) that catalyzes formation of *trans*-decalin from an acyclic substrate. Computational studies on the reaction mechanisms rationalizes both the substrate- and stereoselectivity of the enzyme.

### Graphical Abstract



Cycloaddition reactions such as intramolecular Diels–Alder (IMDA) reactions are extremely important and versatile synthetic transformations that allow the construction of multicyclic scaffolds with stereochemical control and atom economy.<sup>1</sup> Recent findings revealed that

**Corresponding Author.** yitang@ucla.edu, houk@chem.ucla.edu, kenji55@u-shizuoka-ken.ac.jp.

#### ASSOCIATED CONTENT

##### Supporting Information

Experimental details, spectroscopic and computational data. This material is available free of charge via the Internet at <http://pubs.acs.org>.

The authors declare no competing financial interests.

nature has evolved enzymes to catalyze [4+2] reactions in natural product biosynthetic pathways.<sup>2</sup> Especially from bacterial pathways, a few so-called “Diels-Alderase (DAase)” have been discovered and characterized, including those from the spinosyn,<sup>3</sup> solanapyrone,<sup>4</sup> tetronate/tetramate containing compounds,<sup>5</sup> thiopeptides<sup>6</sup> and abyssomycin<sup>7</sup> pathways. Structural studies suggest that while there are no conserved sequences for DAases, these enzymes provide an active site environment that accelerates or enables the cycloaddition reactions to occur.<sup>7,8</sup> The diversity of DAases found so far inspires the discovery of additional enzymes that can catalyze such reactions, which can enable genome mining of new natural products that contain structural features that are derived from cycloaddition reactions.

IMDA reactions are also proposed to occur widely among fungal natural product pathways, in particular those of polyketide and polyketide-nonribosomal peptide natural products.<sup>9</sup> For example, both the *trans*-decalin and isoindolone ring systems found in lovastatin<sup>10</sup> and cytochalasan,<sup>11</sup> respectively, are thought to arrive from cycloaddition reactions from acyclic precursors. Decalin-containing fungal polyketides constitute a large class of natural products with a diverse array of biological activities (Figures 1 and S1). Biosynthesis of the acyclic substrates that contain both the dienophile and the diene are proposed to be catalyzed by the iterative functions of the highly-reducing polyketide synthases (HR-PKSs). While bioinformatic analysis and genetic evidences have suggested a class of lipocalin-like enzymes may be involved in the formation of the decalin ring systems of Sch210972<sup>12</sup> and equisetin,<sup>13</sup> no direct biochemical evidence of enzyme-catalyzed IMDA reaction has been described. This is in part due to the inability to capture an acyclic substrate required for activity verification. In this work, we provide biochemical confirmation of DAase activity from a fungal polyketide-nonribosomal peptide biosynthetic pathway, using the biosynthesis of myceliothermophin as a model system.

Myceliothermophins, including myceliothermophin E (**1**) and myceliothermophin A (**2**), are cytotoxic compounds isolated from the thermophilic fungus *Myceliophthora thermophila* (Figure 1).<sup>14</sup> **1** exhibits IC<sub>50</sub> values of <100 nM towards a variety of cancer cell lines. Multiple total syntheses of myceliothermophins have been accomplished to establish the absolute stereochemistry as shown in Figure 1.<sup>15,16</sup> Both **1** and **2** contain a *trans*-fused decalin ring system connected to a conjugated 3-pyrrolin-2-one moiety, with **1** containing an exocyclic methylpropylidene unit derived from leucine at C21, while **2** is substituted with a hydroxyl group at the same position. Despite the wide occurrence of the 3-pyrrolin-2-one ring system in natural products (Figure S1),<sup>17</sup> the formation of this ring system has not been widely studied. The pyrrolinone is proposed to derive from a Knoevenagel condensation between the  $\alpha$ -carbon C19 and a reductively released amino aldehyde C20. This differs from the tetramic acid rings found in equisetin and Sch210972, which arise from Dieckmann cyclization of aminoacylated polyketides.<sup>18</sup>

To investigate the biosynthetic pathway of **1** and **2**, the genome of the producing organism *M. thermophila* ATCC 42462 was queried for the presence of PKS-NRPS containing genes. Two PKS-NRPS genes were found, and analysis of the neighboring genes indicated that MYCTH\_78013 (named *mycA*), which is near the end of a chromosome, is a likely candidate (Table S2). Immediately adjacent is *mycB* encoding a potential DAase that has

sequence homology (36% identity) to CghA, which has been implicated to be involved in the cycloaddition during Sch210972 biosynthesis.<sup>12</sup> A *trans*-acting enoylreductase (ER) is encoded in *mycC* (Figure 2A). This three-gene cassette is found widely among sequenced fungi (Figure S10). To test the link between the gene cluster and production of **1** and **2**, which are produced by the wild type strain at yields of 6mg/L and 50 mg/L, respectively (Figure 2B, i) (Figures S11–S12, Table S3–S4), deletion strain of *mycA* was generated through gene replacement (Figure S2). LC-MS analysis showed that deletion of *mycA* completely abolished the production of **1** and **2** (Figure 2B, ii), confirming the involvement of MycA in their biosynthesis. Comparison of the LC-MS traces also revealed the abolishment of two additional compounds, **3** and **4**, with the same  $m/z$   $[M+H]^+$  of 398 that were not previously reported. Both compounds were purified from the wild type strain at yields of 10 mg/L (**3**) and 16 mg/L (**4**) as shown in Figure 2C.

Structural characterization with NMR showed **3** is an acyclic polyolefinic compound that contains a 4-pyrrolin-2-one moiety, which is in conjugation with the enol at C18 via the  $\alpha$ -carbon at C19 (Figure 2C and Figures S13, S20–24, Tables S5). This is likely the enolized form of the PKS-NRPS/ER product, which contains eight differentially  $\alpha$ - and  $\beta$ -functionalized ketide units aminoacylated with leucine, and has undergone Knoevenagel condensation (Figure 4). To confirm that **3** is synthesized by PKS-NRPS and ER, we introduced both *mycA* and *mycC* into the heterologous host *Aspergillus nidulans* A1145 (Figure S4). Compared to the untransformed host, *A. nidulans* expressing MycA and MycC showed clear accumulation of a new compound that is identical to **3** in retention time, UV absorbance and mass (Figure 2B, v). This result suggests the *myc* PKS-NRPS and its ER partner are sufficient to form the pyrrolinone moiety, in contrast to previous work with other R-domain containing fungal PKS-NRPS systems.<sup>19</sup>

On the other hand, **4** is the *trans*-decalin cyclized form of **3** and contains the enolized dienyl pyrrolinone ring (Figures S14, S25–30, Tables S6). This compound therefore represents the potential intermediate that can be oxidized into both **1** and **2**. To examine the role of MycB on the formation of **1**, **2**, and **4** in *M. thermophila*, we generated the *mycB* strain (Figure S3). LC-MS analysis of the metabolites showed that all these cyclized products were abolished, leaving the acyclic **3** as the dominant product (Figure 2B, iii). Hence, MycB is directly involved in the cycloaddition to form the decalin ring. This is further verified when the entire three-gene cassette *mycABC* was introduced into *A. nidulans* (Figure 2B, iv). Analysis of the extract showed that compared to *mycAC* alone, introduction of *mycB* led to emergence of cyclized product **4** as well as the final metabolite **1**. We were not able to detect **2** in this strain, suggesting that the stereoselective hydroxylation of C21 is likely catalyzed by additional enzyme only present in *M. thermophila*. Analysis of the nearby genes to the *myc* cluster did not reveal any oxygenases that may perform this reaction (Figure S2), hence the enzyme may be shared with other pathways in the strain.<sup>20</sup>

In comparing the various extracts analyzed in Figure 2B, we noted a new compound **5** that is consistently found in *M. thermophila mycB* strain, and the transformed *A. nidulans* strains. This compound has  $m/z$   $[M+H]^+$  of 396 and  $\lambda_{\max}$ =327 nm (Figure S15), both of which closely resemble those of **1**. Purification of **5** from the *mycB* strain (3 mg/L) followed by NMR characterization (Figure S31–35) revealed the new compound is the acyclic form of **1**,

which is consistent with its accumulation in the *mycB* and in the *A. nidulans mycAC* strains. We propose that **5** could be an air oxidation product of **3**, via likely the same mechanism as oxidation of **1** from **4**. We attribute the accumulation of **3** and **5** in the *A. nidulans mycABC* strain to be insufficient activity of MycB and/or differences in the redox environment compared to the original producer. Indeed, expressing a second copy of the *mycB* gene does lead to decrease of **5** and increased amount of **4** and **1** (Figure S7).

To confirm that MycB is indeed a DAase, *N*-FLAG-tagged recombinant enzyme was heterologously expressed and purified from *Saccharomyces cerevisiae* BJ5464-NpgA (0.2 mg/L, Figure S5). Either 0.2 mM **3** or **5** was then incubated with 1  $\mu$ M MycB in Tris Buffer, pH 7.4 and formation of cyclized products were assayed by LC-MS (Figure 3A). No conversion of **3** to **4** was detected under prolonged incubation (the compound degrades after overnight assay), while complete conversion of **5** to **1** can be observed in three hours (Figure 3A and 3B). Control incubation in the absence of MycB led to degradation of **5** (Figure S6). All chromatographic and spectroscopic properties of **1** from the in vitro assay matches to that purified from in vivo reaction (Figure 2B), illustrating MycB can catalyze the IMDA reaction with regio- and stereospecific control. The kinetic properties of MycB was measured to give a  $K_M$  of  $\sim 75 \mu\text{M}$  towards **5**, and a  $k_{\text{cat}}$  of  $\sim 0.9 \text{ sec}^{-1}$  (Figure 3C).

The in vitro results confirmed that MycB can indeed catalyze the Diels–Alder reaction to convert the C18-keto containing **5** into the cytotoxic natural product **1**. The failure of MycB to catalyze the conversion of C18-enol **3** into **4**, however, suggests differential reactivity towards the ketone and enol substrates. This difference also leads to a proposal of the *myc* pathway as shown in Figure 4, to account for the isolation of the metabolites **1–5**. Following MycA-catalyzed construction and release of the aminoacyl polyketide aldehyde **6**, a Knoevenagel condensation yields the expected ketone product **7**. We propose that most likely, this ketone is the natural substrate of MycB, leading to formation of the *endo* product **8**. The keto-3-pyrrolin-2-one can readily enolize to form the observed **4**. When MycB is inactivated, the acyclic **7** can also readily enolize to form **3**, which is not reactive towards MycB catalyzed IMDA reaction. However, both **3** and **4** may undergo spontaneous air oxidation to yield **5** and **1**, respectively. Indeed, when **4** was dissolved in methanol at 37°C for 16 hours, formation of **1** was observed along with an equimolar release of H<sub>2</sub>O<sub>2</sub> from the reaction (Figures S7 and S8). A proposed oxidation mechanism that involves sequential single electron reduction of O<sub>2</sub>, during which the C18 enol hydrogen is first abstracted, is shown in Figure S9. Significantly (and serendipitously), formation of **5** prevents further tautomerization of the 3-pyrrolin-2-one ring system and results in a stable C18-keto, acyclic substrate for MycB.

To support the proposed pathway and rationalize the reactivity difference between the C18 ketone and enol substrates in the IMDA reaction, we performed density functional theory (DFT) studies on model substrates and products (**1'–8'**) in which the isobutyl group in **1–8** is replaced by a methyl group. The enols **3'** and **4'** were found to be more stable than the corresponding ketones **7'** and **8'**, respectively, with  $G$  of  $-8.0$  and  $-3.5$  kcal/mol, respectively (Figure 4), supporting the rapid enolization of **7** into **3**, in the absence of MycB.

We then calculated the energetics of the three potential DA reactions shown in Figure 4, starting with either **7'**, **3'** or **5'**. In each of these cases, the uncatalyzed DA reactions are very slow, with similar  $G_{\text{uncat}}^{\ddagger}$  values of  $\sim 24 - 25$  kcal/mol (Figures S36–38). This corresponds to rate constants of  $\sim 10^{-5} \text{ sec}^{-1}$  at room temperature according to transition state theory. In contrast, the spontaneous DA reaction in the biosynthesis of Sch210972 or equisetin is very fast.<sup>12</sup> The DA reaction of the enol precursor of Sch210972 has a barrier of only 12 kcal/mol, because of the additional electron-withdrawing keto group in the tetramate moiety.<sup>12</sup> Interestingly, with **7'**, the uncatalyzed reaction is predicted to produce a mixture of diastereomers (Figure 4, dash box), with the unobserved *cis*-fused decalin **9'** being the major isomer, resulting from the lower energy transition state TS-7'-*exo*. We propose that a suitable acidic residue in the active site of MycB may accelerate the reaction, by lowering the LUMO of the dienophile and stabilization of the transition state, through hydrogen bonding to the C18-carbonyl group (in **7** and **5**, but not **3**) next to the dienophile. Such catalytic role for a hydrogen bond donating residue is also proposed based on the structures of SpnF and PyrI4.<sup>8</sup> Additionally, because TS-7'-*endo* is more asynchronous than TS7'-*exo*, we envisioned that such a catalyst would stabilize the more polarized *endo* transition state than the *exo* transition state. To test our hypothesis, we used *p*-cresol as a model to probe effects of possible catalytic residues such as a tyrosine in the active site of the enzyme (Figure S39). The results showed that the catalyzed DA reaction of either **7'** or **5'** is much faster, with  $G_{\text{cat}}^{\ddagger}$  of  $\sim 19$  kcal/mol. This corresponds to a rate constant of  $\sim 0.1 \text{ sec}^{-1}$  at room temperature, which agrees with the experimentally measured rate ( $k_{\text{cat}}$  of  $\sim 0.9 \text{ sec}^{-1}$ , Figure 3C). Also as predicted, the catalyzed DA reaction of **7'** is computed to be *endo*-selective to give **8'**, in agreement with assay results. The hydrogen bond distance in the *endo* transition state (TS-7'-Y-*endo*) is shorter than that of the *exo* transition state (1.74 Å versus 1.83 Å), due to the more polarized nature of the *endo* TS. In contrast, the hydrogen bond from cresol to the corresponding enol oxygen in **3'** has only a minimal effect on the rate of its DA reaction, with  $G_{\text{cat}}^{\ddagger} = 23.9$  kcal/mol. This is in agreement with the experimental observation that MycB could not catalyze the DA reaction of enol **3**.

In summary, the nanomolar cytotoxic **1** is synthesized by a concise three-enzyme pathway. Our findings expand the collection of long sought-after DAases from fungi, and may lead to discovery of new decalin-containing natural products using MycB as a signature biosynthetic marker as shown in Figure S10.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.


## Acknowledgments

This work was supported by the NIH (1DP1GM106413 and 1R35GM118056), and the NSF (CHE-1361104 to K.N.H.), and JSPS Program for Advancing Strategic International Networks to Accelerate the Circulation of Talented Researchers (No. G2604 to K.W.).


## REFERENCES

1. Takao, K-i, Munakata, R., Tadano, K-i. Chem. Rev. 2005; 105:4779. [PubMed: 16351062]

2. (a) Klas K, Tsukamoto S, Sherman DH, Williams RM. *J. Org. Chem.* 2015; 80:11672. [PubMed: 26495876] (b) Kim HJ, Ruszczycky MW, Liu H-w. *Curr. Opin. Chem. Biol.* 2012; 16:124. [PubMed: 22260931] (c) Zheng Q, Tian Z, Liu W. *Curr. Opin. Chem. Biol.* 2016; 31:95. [PubMed: 26870924]
3. Kim HJ, Ruszczycky MW, Choi S-h, Liu Y-n, Liu H-w. *Nature.* 2011; 473:109. [PubMed: 21544146]
4. Oikawa H, Katayama K, Suzuki Y, Ichihara A. *J. Chem. Soc., Chem. Commun.* 1995; 13:1321.
5. (a) Tian Z, Sun P, Yan Y, Wu Z, Zheng Q, Zhou S, Zhang H, Yu F, Jia X, Chen D, Mándi A, Kurtán T, Liu W. *Nat. Chem. Biol.* 2015; 11:259. [PubMed: 25730548] (b) Hashimoto T, Hashimoto J, Teruya K, Hirano T, Shin-ya K, Ikeda H, Liu H-w, Nishiyama M, Kuzuyama T. *J. Am. Chem. Soc.* 2015; 137:572. [PubMed: 25551461]
6. (a) Wever WJ, Bogart JW, Baccile JA, Chan AN, Schroeder FC, Bowers AA. *J. Am. Chem. Soc.* 2015; 137:3494. [PubMed: 25742119] (b) Hudson GA, Zhang Z, Tietz JI, Mitchell DA, van der Donk WA. *J. Am. Chem. Soc.* 2015; 137:16012. [PubMed: 26675417]
7. Byrne MJ, Lees NR, Han L-C, van der Kamp MW, Mulholland AJ, Stach JEM, Willis CL, Race PR. *J. Am. Chem. Soc.* 2016; 138:6095. [PubMed: 27140661]
8. (a) Fage CD, Isiorho EA, Liu Y, Wagner DT, Liu H-w, Keatinge-Clay AT. *Nat. Chem. Biol.* 2015; 11:256. [PubMed: 25730549] (b) Zheng Q, Guo Y, Yang L, Zhao Z, Wu Z, Zhang H, Liu J, Cheng X, Wu J, Yang H. *Cell Chem. Biol.* 2016; 23:352. [PubMed: 26877021]
9. Minami A, Oikawa H. *J. Antibiot. (Tokyo).* 2016; 69:500. [PubMed: 27301662]
10. Auclair K, Sutherland A, Kennedy J, Witter DJ, Van den Heever JP, Hutchinson CR, Vederas JC. *J. Am. Chem. Soc.* 2000; 122:11519.
11. Scherlach K, Boettger D, Remme N, Hertweck C. *Nat. Prod. Rep.* 2010; 27:869. [PubMed: 20411198]
12. Sato M, Yagishita F, Mino T, Uchiyama N, Patel A, Chooi YH, Goda Y, Xu W, Noguchi H, Yamamoto T, Hotta K, Houk KN, Tang Y, Watanabe K. *Chem Bio Chem.* 2015; 16:2294.
13. Kato N, Nogawa T, Hirota H, Jang J-H, Takahashi S, Ahn JS, Osada H. *Biochem. Biophys. Res. Commun.* 2015; 460:210. [PubMed: 25770422]
14. Yang YL, Lu CP, Chen MY, Chen KY, Wu YC, Wu SH. *Chem. Eur. J.* 2007; 13:6985. [PubMed: 17503417]
15. Nicolaou K, Shi L, Lu M, Pattanayak MR, Shah AA, Ioannidou HA, Lamani M. *Angew. Chem. Int. Ed.* 2014; 53:10970.
16. Shionozaki N, Yamaguchi T, Kitano H, Tomizawa M, Makino K, Uchiro H. *Tetrahedron Lett.* 2012; 53:5167.
17. (a) Kontnik R, Clardy J. *Org. Lett.* 2008; 10:4149. [PubMed: 18698786] (b) Suzuki S, Hosoe T, Nozawa K, Kawai K-i, Yaguchi T, Udagawa S-i. *J. Nat. Prod.* 2000; 63:768. [PubMed: 10869198] (c) Osterhage C, Kaminsky R, König GM, Wright AD. *J. Org. Chem.* 2000; 65:6412. [PubMed: 11052082] (d) West RR, Van Ness J, Varming AM, Rassing B, Biggs S, Gasper S, McKernan PA, Piggott J. *J. Antibiot. (Tokyo).* 1996; 49:967. [PubMed: 8968388] (e) Singh SB, Goetz MA, Jones ET, Bills GF, Giacobbe RA, Herranz L, Stevens-Miles S, Williams DL Jr. *J. Org. Chem.* 1995; 60:7040.
18. (a) Liu X, Walsh CT. *Biochemistry.* 2009; 48:8746. [PubMed: 19663400] (b) Sims JW, Schmidt EW. *J. Am. Chem. Soc.* 2008; 130:11149. [PubMed: 18652469]
19. (a) Song Z, Bakeer W, Marshall JW, Yakasai AA, Khalid RM, Collemare J, Skellam E, Tharreau D, Lebrun M-H, Lazarus CM, Bailey AM, Simpson TJ, Cox RJ. *Chem. Sci.* 2015; 6:4837. (b) Fuji R, Minami A, Gomi K, Oikawa H. *Tetrahedron Lett.* 2013; 54:2999. (c) Niehaus E-M, Kleigrew K, Weimann P, Studt L, Sieber CMK, Connolly LR, Freitag M, Guldener U, Tudzynski B, Humpt H-U. *Chem. Biol.* 2013; 20:1066.
20. Tsunematsu Y, Ishikawa N, Wakana D, Goda Y, Noguchi H, Moriya H, Hotta K, Watanabe K. *Nat. Chem. Biol.* 2013; 9:818. [PubMed: 24121553]



**Figure 1.**  
Structures of decalin containing fungal polyketides and polyketide-amino acid hybrids.

**Figure 2.**

Verification of the myceliothermophin gene cluster. (A) The *myc* cluster encodes the PKS-NRPS MycA (domain abbreviations: KS: ketosynthase; AT: acyltransferase; DH: dehydratase; MT: methyltransferase; KR: ketoreductase; ACP: acyl carrier protein; C: condensation; A: adenylation; PCP: peptidyl carrier protein; and R: reductase); the *in trans* enoylreductase (ER) MycC; and the putative DAse MycB; (B) Product profile of wild type and single-gene knockout strains of *M. thermophila*; and that of *A. nidulans* transformed




with combinations of *myc* genes; (C) structures of metabolites isolated. The stereochemistries of **3**, **4** and **5** are assumed to be similar to **1**.

Author Manuscript


Author Manuscript

Author Manuscript

Author Manuscript



**Figure 3.** Activity of the DAase MycB. (A) MycB can catalyze the cycloaddition of the ketone **5** to **1**, but is not reactive towards the enol **3**. (B) Time course analysis of the conversion of **5** to **1**. The starting concentrations for **5** and MycB are  $200 \mu\text{M}$  and  $1 \mu\text{M}$ , respectively. (C) Saturation kinetics of MycB. Each data point performed in triplicate.



**Figure 4.**

The proposed biosynthetic pathway of **1** based on isolated natural products and biochemical characterization of MycB. DFT analysis were performed on model substrates (**1'**–**8'**) of which the isobutyl group in **1**–**8** is replaced by a methyl group. Calculations were performed at the CPCM (water)/M06-2X/6-311+G(d,p)//M06-2X/6-31G(d) level of theory. The computed free energies of model compounds are shown in parenthesis. Calculations of stereoselectivity under uncatalyzed and catalyzed conditions are shown in the dash box.